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OBJECTIVES The purpose of this study was to determine factors correlating with the risk of postoperative
mortality after transmyocardial laser revascularization (TMR).
BACKGROUND Clinical studies have indicated that TMR reduces angina by an average of two classes in
patients with medically refractory symptoms not treatable by coronary artery bypass graft
(CABG) or percutaneous transluminal coronary angioplasty. Factors which correlate with
mortality after TMR, however, have not been extensively investigated.
METHODS One hundred thirty-two patients with severe angina underwent TMR as sole therapy with a
CO2 laser. Age, gender, ejection fraction, prior CABG, unstable angina and the severity of
coronary artery disease (graded on the basis of a newly proposed Anatomic Myocardial
Perfusion index, AMP) were each determined. Each vascular territory (left anterior
descending artery [LAD] left circumflex artery and posterior descending artery [PDA]) was
graded as either having (AMP 5 1) or not having (AMP 5 0) blood flow through an
unobstructed major vessel in the territory. Univariate and multivariate analysis determined
which factors correlated with mortality.
RESULTS Patients with at least one AMP 5 1 vascular territory (overall AMP 5 1) had a 5% (4/82)
postoperative mortality rate (POM), compared with 25% (12/49) with overall AMP 0 (p 5
0.002). Left anterior descending artery AMP (p 5 0.03) and previous CABG (p 5 0.04) each
correlated with the risk of POM. However, multivariate analysis indicated that no factor
improved the correlation obtained with overall AMP by itself. With regard to overall
mortality (Kaplan-Meier curves), univariate analysis also revealed correlations with overall
AMP (p , 0.001), LAD AMP (p 5 0.005), previous CABG (p 5 0.003) and PDA AMP
(p 5 0.05) each individually correlated with mortality. Multivariate analysis indicated that
overall AMP 5 1, female gender and previous CABG together correlated best with lower
postoperative mortality.
CONCLUSIONS Patients with good blood flow to at least one region of the heart through a native artery or
a patent vascular graft have a markedly reduced risk of perioperative and longer term
mortality. (J Am Coll Cardiol 1999;34:55–61) © 1999 by the American College of
Cardiology
Transmyocardial laser revascularization (TMR) is currently
being evaluated as a therapy for patients with refractory
angina who cannot be treated with bypass surgery or
angioplasty because of diffuse coronary artery disease (1).
From a clinical perspective, most attention has focused on
the common finding that this therapy is effective in reducing
angina by an average of two classes in these otherwise
untreatable patients (2–7). There have also been reports of
mild to modest improvements in regional blood flow ap-
pearing most consistently between three and six months
after the surgery (2–5). Exercise tolerance, when examined,
also appears to be improved (8,9).
Despite having now accrued significant clinical experi-
ence with this procedure (with reports of up to 4,000
procedures having been performed worldwide), much less
attention has focused on understanding factors that may
predict which patients benefit most and which are at
increased risk of morbidity and mortality from this proce-
dure. Perioperative mortality rates between 3% and 20%
have been reported (2–5,7); the reason for this wide range is
unknown. Patient eligibility criteria have varied significantly
among various ongoing and completed studies and among
different investigators, but a generally accepted set of criteria
has not emerged. The purpose of this study is to investigate
factors that correlate with the risk of mortality after TMR.
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Physiologic considerations. It was originally proposed
that myocardial perfusion could be achieved by the creation
of transmyocardial channels which communicate with the
left ventricular cavity (1), thus mimicking the physiology of
blood flow in reptile hearts (10). However, results of
physiologic and anatomic studies in experimental animal
models have suggested that blood does not flow through
these channels (11–17). This is particularly the case for the
acute setting, where it has been demonstrated that TMR
channels do not protect myocardial viability in the face of
severe acute ischemia (18–20). If applicable to the clinical
setting, these findings would suggest that patients undergo-
ing TMR may not derive any perfusion benefit in the days
after the procedure. It is therefore possible that patients who
are particularly susceptible to ischemia may be at increased
risk of perioperative morbidity and mortality because of the
stress associated with surgery and the postoperative recovery
period. This, in combination with other physiologic con-
siderations (see Discussion), has led to the hypothesis that
patients with severe unbypassed three-vessel (or unbypassed
left main) disease who lack any areas of myocardium
protected by blood flow through patent vessels are at
increased risk of perioperative mortality after TMR.
METHODS
Between February 1994 and October 1996, 132 patients
with medically refractory class III and IV angina underwent
TMR as sole therapy with a CO2 laser (The Heart Laser,
PLC Systems Inc., Franklin, Massachusetts) at the Audu-
bon Heart Center in Louisville, Kentucky by a single
operator (A.M.L.). These subjects took part in an investi-
gation of the safety and efficacy of TMR in which the
Audubon Heart Center participated. Each patient provided
informed consent after being told of the risks and potential
benefits of participating in the study. The protocols under
which the studies were conducted were approved by the
local ethics committee. The present study is a retrospective
analysis of the data collected from those patients.
Demographic and medical data were collected on all 132
patients. A preliminary evaluation of many factors and
survey of published reports had indicated that the most
relevant factors to examine more closely were age, gender,
ejection fraction, the presence of prior bypass surgery, the
occurrence of unstable angina in the preoperative period and
the severity of coronary artery disease. The severity of
coronary vascular disease was graded on the basis of angio-
graphic findings as detailed below.
Review and grading of coronary angiograms. The origi-
nal angiograms of 109 of the patients were retrieved and
reviewed by one of the cardiologists participating in this
study (D.B. or J.R.R.) who was blinded as to whether the
patient did or did not die any time during the follow-up
period. For those patients whose angiogram could not be
retrieved for review, grading of the extent of vascular disease
was based on the report of the most recent angiogram;
again, this was also done without knowledge of outcome.
The severity of coronary artery disease was graded according
to what we have termed the “Angiographic Myocardial
Perfusion (AMP) score.” The intent of the AMP score is to
provide a simple system for designating whether there is or
is not an unobstructed path for blood flow to and through
the major vessel of a specified region of the heart. In the case
that such an unobstructed path exists, the region may be
considered to be protected, in the sense that it should not be
vulnerable to ischemia during times of stress. Inherent to
this grading system is the notion that the path for blood
flow may be either entirely through the native vasculature or
it may include surgically placed conduits. Each of the three
major vascular territories (anterior, lateral and inferior) was
graded separately according to the following definitions. A
region was considered to have an AMP score of “1” if
myocardial perfusion was provided through a major vessel in
the region, and the path for blood flow (be it through native
vessels or through vascular grafts) was not affected by
hemodynamically significant stenoses (i.e., no greater than
50% lumenal narrowings). A region was considered to have
an AMP score of “0” if myocardial perfusion in the region
was only provided through minor vessels or through vessels
with hemodynamically significant stenoses (lumenal nar-
rowings $50%). In addition to grading each region indi-
vidually, an overall AMP score was designated as “1” if there
was at least one AMP 1 region on the heart; otherwise the
overall AMP score was designated as “0”. Guidelines were
established to identify “major” vessels in each of the three
regions. The left anterior descending artery (LAD) was
considered the major vessel for the anterior wall. For the
lateral wall, any large caliber marginal branch which reached
at least three quarters of the distance from the base to the
apex of the heart was considered a major vessel. Similarly,
any large caliber posterior descending artery which reached
at least three quarters of the distance between the base and
the apex of the heart was considered to be a major vessel.
Statistical methods. Data are presented as mean 6 SD.
The Fisher exact test was used to identify variables which
might be related to perioperative mortality (death within 30
days of surgery). Age, gender, ejection fraction, presence of
unstable angina, prior coronary artery bypass graft (CABG)
experience, anterior AMP, lateral AMP, inferior AMP and
overall AMP were also examined using logistic regression.
The log-rank test and Cox regression were used to investi-
Abbreviations and Acronyms
AMP 5 Anatomic Myocardial Perfusion index
CABG 5 coronary artery bypass graft
EF 5 ejection fraction
LAD 5 left anterior descending artery
TMR 5 transmyocardial revascularization
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gate whether any variables or combination of variables were
significant predictors of overall survival. Survival curves were
estimated using the Kaplan-Meier procedure (21). Hypoth-
eses were tested against two-sided alternatives, and signifi-
cance levels were set at 0.05.
To test whether there was a “training effect” (i.e., if
mortality decreased as the operator gained experience),
surgical date was entered as an additional variable. The
results of that analysis showed that surgical date did not
impact on survival; this factor will not be discussed further.
There were 132 patients in the data set. Complete data
were available for 129 patients. Ejection fraction was not
available for two patients and AMP scores were not avail-
able for one of the patients. For univariate analyses, all
available data on the covariate of interest were used. In the
multivariate analysis, only data from patients with complete
data were used. The SAS (Cary, North Carolina) software
system, Release 6.12, was used for all analyses.
RESULTS
Patient characteristics are summarized in Table 1. For the
group as a whole, mean age was 61.1 6 11.3 years. Men
constituted 82.6% of the patient population, and most
patients suffered from class IV angina (95%). Ejection
fraction was generally well preserved, averaging 44 6 12%.
Most patients (84%) had a history of at least one bypass
surgery in the past. Nearly half of the patients were classified
as having unstable angina requiring intravenous heparin and
nitroglycerine before the surgery. Most patients (62%) had
an overall AMP score of 1, indicating that they had at least
one well perfused region of the heart. The anterior region
was protected (i.e., anterior AMP score 5 1) in 39% of the
cases and was the single most frequently well perfused
region; this compares with 24% of patients having a pro-
tected lateral wall and only 18% of patients having a
protected inferior wall. Table 2 provides further detail
concerning the type of vessels providing myocardial protec-
tion. Among the 132 patients studied, there were a total of
110 protected regions (Tables 1 and 2). Of these, 30 were
protected by native vessels, 50 by saphenous veins and 28
(for the anterior region) by internal mammary arteries as
further detailed in Table 2. For the anterior region, the
mammary artery was the most frequent means of protection,
accounting for more than 50% of the cases.
The degree of angina (graded according to the Canadian
Cardiovascular Society Angina Score) was severe before
surgery, with approximately 95% of patients suffering with
class IV symptoms and the remainder suffering with class III
symptoms. At the time of the last available follow-up in the
100 patients who survived and were followed for at least 6
months, 50% were classified with class I angina, 25% had
class II angina, 8% had class III angina and 11% had class
IV angina; follow-up angina class was unavailable for 6% of
these patients. Seventy-two percent of the patients experi-
enced a reduction of angina symptoms of two or more
classes, 10% improved by one class, whereas 11% showed no
improvement. In 7% of cases, improvement could not be
assessed due to missing data. Thus, in surviving patients,
there was substantial subjective symptomatic improvement
in angina.
Sixteen of the original 132 patients (12.1%) died within
the first 30 days after surgery. An additional 13 deaths
occurred between 30 days and 1 year after surgery (total
one-year mortality 22%). Eight patients died more than one
year after surgery, and the remainder were alive at their last
Table 1. Summary of Characteristics of All Patients
Characteristic All Patients
n 132
Age (yr)* 61.1 6 11.3 (35–84)
Gender
Male 109
Female 23
Preoperative angina score
Class III 7
Class IV 125
Ejection fraction* 44 6 12 (15–68)
Previous CABG
Yes 111
No 21
Unstable angina
Yes 63
No 69
Anterior AMP
Unknown 1
1 52
0 79
Lateral AMP
Unknown 1
1 32
0 99
Inferior AMP
Unknown 1
1 24
0 107
Overall AMP
Unknown 1
1 82
0 49
*Mean 6 standard deviation (range).
AMP 5 Anatomic Myocardial Perfusion index score; CABG 5 coronary artery
bypass graft.
Table 2. Breakdown of Vessel Type Supplying “Protected”
Regions
Protected
Region n
Native
Vessel
Saphenous
Vein
Mammary
Artery
Anterior 52 9 16 27
Lateral 32 12 19 n/a
Inferior 24 9 15 n/a
Total 108 30 50 27
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follow-up visit. Patients known to be alive at last follow-up
had a median follow-up duration of 12.25 months. Overall
1-year survival is estimated to be 75%. The causes of death
are summarized in Table 3. Most deaths were attributable to
cardiovascular causes.
Results of univariate analysis indicated that perioperative
mortality was significantly associated with overall AMP
score, anterior AMP score and whether or not the patient
had previous CABG (Table 4). Overall AMP score was the
strongest predictor of perioperative mortality; patients with
an overall AMP score of 1 were over six times less likely to
experience perioperative mortality (p 5 0.002, Fisher exact
test). An anterior AMP score of 1 was associated with a
five-fold decrease in the likelihood of perioperative mortal-
ity (p 5 0.03). Patients with previous CABG were four
times less likely to die in the perioperative period (p 5
0.04). Although patients with unstable angina were almost
twice as likely to die in the perioperative period, this was not
statistically significant. Also of note is that none of the 23
women died in the perioperative period, whereas 16 of the
109 men (15%) experienced perioperative mortality. This
difference was not statistically significant. None of the other
covariates considered were significantly related to perioper-
ative mortality. When overall AMP score was entered in a
multivariate logistic model, no other variables added signif-
icantly to the ability to predict perioperative mortality.
With respect to overall mortality, patients with overall
AMP scores of 1 had significantly better survival compared
with patients with a score of 0 (p , 0.0.001, Fig. 1).
Anterior AMP score 5 1 (p 5 0.005, Fig. 2), previous
CABG (p 5 0.003, Fig. 3) and inferior AMP score 5 1
(p 5 0.05, Fig. 4) were also predictors of improved survival
when considered individually. Multivariate analysis using a
backward selection procedure resulted in a model with three
covariates: overall AMP score, previous CABG and gender.
The risk ratios and 95% confidence intervals for these
variables in combination are shown in Table 5. Men with
overall AMP score of 0 without previous CABG had the
lowest predicted survival curve, with an estimated 1-year
mortality exceeding 60%.
Figure 1. Kaplan-Meier curves depicting survival in patients
having (overall anatomic myocardial perfusion index score [AMP]
5 1) or not having (overall AMP 5 0) unobstructed blood flow to
a major vessel in at least one vascular territory. On the basis of
univariate analysis, this factor was the strongest single factor which
correlated with the risk of mortality after transmyocardial revas-
cularization (TMR) (p 5 0.002).
Figure 2. Kaplan-Meier curves depicting survival in patients
having (anterior AMP 5 1) or not having (anterior AMP 5 0)
unobstructed blood flow to the left anterior descending artery. On
the basis of univariate analysis, this factor also correlated with the
risk of mortality after TMR (p 5 0.005). Abbreviations as in
Figure 1.
Table 3. Cause of Perioperative and Long-Term Deaths
Cause of Death
Perioperative
Death*
Death Between
30 Days and
1 Year
Acute myocardial infarction 7 5
Ventricular fibrillation 3 —
Heart failure 4 3
Cardiac arrest—unspecified
cause
— 4
Respiratory arrest 1 —
Pulmonary embolism 1 —
Stroke 1 —
Uncertain — 1
*One perioperative death was attributed to two factors (stroke and respiratory failure).
Table 4. Results of Univariate Analysis of Factors Correlating
With Risk of Perioperative Mortality
Factor
Perioperative
Mortality
Odds Ratio (95%
Confidence Interval) p*
Overall AMP
AMP 5 0 12/49 5 25% 0.158 0.002
AMP 5 1 4/82 5 5% (0.048–0.524)
Anterior AMP
AMP 5 0 14/79 5 18% 0.186 0.03
AMP 5 1 2/52 5 4% (0.40–0.855)
Previous
CABG
No 6/21 5 29% 0.248 0.04
Yes 10/111 5 9% (0.079–0.780)
Unstable angina
Present 10/63 5 16% 0.505 0.32
Not present 6/69 5 9% (0.172–1.484)
*p values are from Fisher exact test. Abbreviations as in Table 1.
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To assess whether differences in overall mortality associ-
ated with the various risk factors were mainly due to the risk
of postoperative mortality, a separate analysis was performed
which included only patients who survived at least 30 days
after the surgery. This analysis showed that for patients who
survived the 30-day postoperative period, overall AMP
score equal to 1 (p 5 0.006), previous CABG (p 5 0.04),
inferior AMP score equal to 1 (p 5 0.01) and ejection
fractions greater than 45% (p 5 0.02) were each individually
associated with significantly improved survival after the
30-day postoperative period.
For patients with at least one protected region, there were
a total of only 9 deaths, 4 in the perioperative period and 5
late deaths. Among this small patient group, 6 patients had
only 1 protected region and 3 patients had 2 protected
regions. Mammary arteries, saphenous veins and native
vessels were roughly equally represented in this small patient
group. On the basis of this analysis and the analysis
provided in Table 2, there is nothing to indicate that
mammary arteries were more protective than saphenous
veins or native vessels. An additional factor that was tested
was whether older graphs provided less protection. This was
tested using univariate analysis by entering the difference
between the date of last CABG surgery and the TMR date
for subjects who had at least one region of protected
myocardium. This analysis showed that time since last
CABG surgery did not correlate with mortality in this small
patient cohort.
DISCUSSION
The results of this retrospective analysis indicate that
patients with unprotected three-vessel disease (overall AMP
score 5 0) are at high risk of perioperative (;25%) and total
1-year (;40%) mortality after TMR. Of the three vascular
beds, unobstructed blood flow through the LAD (be it
entirely through native vessels or through a patent graft to a
patent distal vessel) was the most important vessel for
predicting survival. Prior CABG afforded a better outcome.
Unstable angina tended to yield a worse outcome, but this
was not statistically significant.
Most of the patients who are considered candidates for
TMR have severe native three-vessel disease. Most patients,
however, have had previous bypass surgery and in many
instances, one or more of the grafts are still patent. Thus,
despite severe native three-vessel disease, one or more of the
major vascular territories is frequently protected by a patent
graft and in such a case this predicts decreased mortality.
Indeed, vascular grafts (either saphenous veins or a mam-
mary artery) were the most frequent (78/108, Table 2)
source of myocardial protection. The age of a vascular graft
did not correlate with bad outcome, though there were very
few patients with protected regions who died. In the present
series, 62% (82/132) of the patients fell into the category of
having at least one well protected region; over 39% of
patients had a well protected LAD system.
Potential mechanisms of benefit. Several factors may
contribute to increased mortality in patients with severe
unprotected three-vessel coronary artery disease. First, re-
sults of most studies in experimental animal models now
suggest that myocardial perfusion is not increased substan-
tially in the acute setting (11,13,14,20,22). Accordingly, it is
not expected that patients undergoing TMR surgery would
derive an acute perfusion benefit due to the procedure. Yet,
patients with severe three-vessel disease are particularly
prone to ischemia during periods of physical stress such as
Figure 3. Kaplan-Meier curves depicting survival in patients
having had (coronary artery bypass graft [CABG] 5 1) or not
having had (CABG 5 0) previous coronary bypass surgery. On the
basis of univariate analysis, prior CABG predicted a better
outcome after transmyocardial revascularization (TMR) (p 5
0.003).
Figure 4. Kaplan-Meier curves depicting survival in patients
having (inferior AMP 5 1) or not having (inferior AMP 5 0)
unobstructed blood flow to the posterior descending artery. On the
basis of univariate analysis, this exhibited a statistically significant,
though weak correlation with the risk of mortality after TMR (p 5
0.05). Abbreviations as in Figure 1.
Table 5. Risk Ratios for the Three Factors Which Collectively
Provide the Strongest Correlation With Risk of Mortality
Characteristic Risk Ratio
95% Confidence
Interval
Overall AMP score 5 1 0.270 0.129–0.564
Female gender 0.32 0.108–0.945
Previous CABG 0.307 0.132–0.710
Abbreviations as in Table 1.
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would occur during general anesthesia and a thoracotomy,
as well as during the postoperative recovery period. In the
absence of improved perfusion, these patients would be at
increased risk for episodes of myocardial ischemia and
possibly even infarction, which appears to be the major
cause of mortality seen in the group of patients (Table 2). If
this is the primary factor, the risks of this type of therapy
might be reduced if the procedure could be performed
percutaneously, as is currently being developed (23). It may
also be speculated that TMR may disrupt preexistent
collateral vessels that developed in the ischemic area, thus
interfering with collateral flow in the short run.
The reason for an apparent protective benefit of prior
CABG surgery is uncertain. It could reflect a protective
effect of previously placed bypass grafts which have re-
mained patent. Alternatively, the poorer outcome in pa-
tients without prior bypass may be a reflection of more
severe coronary artery disease in subjects who initially
present with diffuse unbypassable lesions.
This study has been limited to an analysis of mortality
after TMR. We have not addressed other aspects of
morbidity because it is not possible to ensure systematic
reporting of all adverse events in a retrospective study such
as this. Clearly, elucidation of the frequency and factors that
predispose to postoperative myocardial infarction, arrhyth-
mias, heart failure, hypotension and other cardiovascular
events is an important topic.
In addition, there has been no detailed analysis of the
efficacy of TMR, other than to report on the change in
angina class in patients who survive the procedure. The
patients of the present study were a subset of patients in a
larger, multicenter study that had been reported on previ-
ously. The authors of those reports suggested that TMR
with the CO2 laser may improve myocardial perfusion (4).
It is also worth specifying that TMR will not alter the
AMP score because TMR, a method of indirect revascular-
ization (as compared with CABG, which would be a
method of direct revascularization), would not affect the
anatomy of the conduit vessels upon which the AMP score
is based.
Study limitations. There are several limitations of this
study. First, there is no control group derived from the same
patient population which received only medical therapy.
Therefore, the mortality of patients with the various risk
factors identified in the present study treated medically is
unknown. However, results of the Coronary Artery Surgery
Study provide some guidelines that help put the results of
the present study in perspective (24). In patients with
preserved ejection fraction (EF .50%) the total, all-cause
one year mortality for patients with three-vessel coronary
artery disease treated medically was ;2%. This increased to
only 3% even in patients with EF ,50%. These quoted
mortality rates were slightly better than reported in the
European Collaborative Study (25) and in the Veterans
Administration Study (26), but in no case were these
one-year mortality rates in medically treated patients greater
than 5%. Although the patients in the present study deemed
to be devoid of any protected region (who generally had
preserved EF) may have suffered with more severe angina
and may have had more severe coronary artery disease, it is
unlikely that mortality in such a group followed medically
would approach the approximately 20% perioperative mor-
tality plus the additional ;20% one-year mortality (total
40% one-year mortality). Furthermore, it could be argued
based on clinical grounds that these rates of perioperative
and one-year mortality identified in the group of patients
without any protected regions would be considered excessive
when compared with the types and magnitude of symptom-
atic improvement being provided by TMR (4).
An additional limitation is that this study is a single-
center study. This has the disadvantage that there may be
some aspects of patient selection, treatment or care that are
unique, and therefore, the results may not extrapolate to all
centers performing TMR. The potential advantage of a
single-center study is in the uniform procedures for patient
selection and treatment. Second, this is a retrospective
analysis and it is well known that such results may not apply
prospectively. Third, there are a relatively small number of
patients and a relatively small number of deaths; therefore
the study may be underpowered to detect the importance of
all factors examined. For example, there was only a small
percentage of women, so the effect of gender on outcome
may not be accurate. Average ejection fraction was near
normal and there were few patients with ejection fractions
less than 30%; therefore, we have not determined the risk of
mortality in patients with ejection fractions lower than this
value. Accordingly, the results of the present study apply to
the group of patients with reasonably well preserved ejection
fractions. Fourth, there was a significant number of patients
who were lost to follow-up after six months. Therefore, the
accuracy of the Kaplan-Meier curves diminishes with time
due to the reduction in number of available patients. Fifth,
patients of this study were treated with a single laser system
(CO2, The Heart Laser). Because the acute tissue effects of
various lasers in clinical use (Ho:YAG, excimer) are differ-
ent, it is possible that the risks of perioperative mortality
may differ with other lasers. Finally, there may be other
factors that contribute importantly to the risk of postoper-
ative mortality that have not been considered.
Summary. In conclusion, when considering TMR for a
patient with severe, unprotected coronary disease in all of
the three major vascular territories, the potential benefits
should be weighed against the possibility of a relatively high
mortality. This study was restricted to an analysis of
mortality, which is an indisputable, objective end point. It
will be equally important to evaluate other end points of
benefit (such as exercise tolerance, myocardial perfusion and
quality of life) in large numbers of patients so that a realistic
estimate of risks and benefits can be provided to patients.
Finally, the results of this retrospective study should not
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necessarily be considered to be generally applicable prospec-
tively, although they may aid with patient selection in some
cases.
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